DE-BIOCORP
19.2.2020 18:02:08 CET | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, today announced an alliance with US-based iSage Rx, LLC., a digital therapeutics company, focused on insulin dose optimization.
In detail, the two companies are committed to integrating their respective technologies to simplify insulin dose capture and optimization. The integration of Mallya (a CE-marked connected device dedicated to insulin pens) into the iSage app (a clinically validated insulin titration platform cleared by the FDA) should enable patients with type 2 diabetes to simplify their insulin management.
This will allow patients with diabetes to seamlessly capture, record, and store information about their insulin injections and while receiving automated guidance on how to adjust their insulin dose overtime ("titration").
Ryan Sysko, President and CEO of Amalgam Rx, Inc, said: "We are very pleased with this partnership to interface Mallya with our iSage app. Combining these two solutions offers to date the most powerful environment for diabetes digitalization and patient support. Together, we can simplify the often complex and confusing journey for patients starting on basal insulin. “
Éric Dessertenne, CEO of BIOCORP, concluded: "For patients with diabetes, the integration of Mallya and iSage provides an additional brick of information to improve their quality of life. For the community of diabetes, this integration is a powerful service platform that takes into account all the clinical and behavioral needs of patients. "
ABOUT ISAGE RX
iSage Rx, manufacturers of the iSage App, the first FDA 510(k)-cleared, prescription-only mobile application for the automated titration of all brands of basal insulin. iSage allows physicians to choose from multiple clinically-validated basal insulin algorithms and tailor the algorithms to the specific needs of their type 2 diabetes patients. iSage Rx is a wholly-owned subsidiary of Amalgam Rx. For more information, visit http://isageapp.com .
ABOUT AMALGAM RX
Amalgam Rx creates custom digital therapies that combine clinical and behavioral health and interventions to engage, support, and improve patient self-management. Led by an experienced team of physicians, behaviorists, technologists, and digital health pioneers, Amalgam Rx strives to use technology to accelerate the impact and scale of medicine to improve the lives of millions of people living with chronic disease. Amalgam does this by partnering with leading life sciences companies to accelerate the R&D and commercialization of digital therapeutics. For more information, visit http://amalgamrx.com/ .
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
.
Follow us on Twitter @BIOCORPSystems
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005728/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TSMC Debuts A13 Technology at 2026 North America Technology Symposium22.4.2026 21:00:00 CEST | Press release
Newest Node Pushes Density Scaling and Energy Efficiency to New Heights to Address Industry’s Most Demanding Applications TSMC (TWSE: 2330, NYSE: TSM) today debuted its latest innovation in its most advanced process technology at the Company’s 2026 North America Technology Symposium. TSMC’s new A13 process is a direct shrink of its industry-leading A14 node announced in 2025, enabling even more compact and efficient designs to address insatiable customer demand in computational requirements for next-generation artificial intelligence, high-performance computing (HPC), and mobile applications. Representing TSMC’s commitment to continuous improvement, A13 provides 6% area savings from A14. Design rules are fully backward compatible with A14, enabling customers to quickly migrate their designs to TSMC’s latest nanosheet transistor technology. In addition, A13 delivers increased power efficiency and performance gains through design-technology co-optimization, and is scheduled to enter prod
Galderma Shareholders Approve All Annual General Meeting Proposals22.4.2026 17:45:00 CEST | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), held earlier today via live webcast. This includes the payment of a gross dividend of 0.35 CHF per dividend-bearing share1, to be distributed out of reserves from capital contributions. Shareholders approved the election of Harry Kirsch as independent member of the Board of Directors, as well as the election of Samuel du Retail and Delphine Viguier-Hovasse, representatives of L’Oréal, as non-independent members of the Board. In addition, Thomas Ebeling (Chair), Daniel Browne, Maria Teresa Hilado, Karen Lee Ling, Roberto Marques, Sherilyn McCoy and Dr. Flemming Ørnskov were re-elected to the Board. The AGM also approved the company’s 2025 Annual Financial Statements, Non-Financial Report and Compensation Report. Detailed voting results and the official minutes will be published on Galderma's
Altrove and Bloomineral Named Winners of the 2026 Grand Prix ACF AutoTech22.4.2026 15:21:00 CEST | Press release
IoT.Bzh receives the inaugural Industrialization Prize at the 9th edition of the international automotive startup competition Altrove and Bloomineral have been crowned winners of the 2026 Grand Prix ACF AutoTech, the international startup competition recognizing the best of automotive innovation. The ninth edition was held on Wednesday, April 15 at the Automobile Club de France in Paris, where IoT.Bzh also received the first-ever Industrialization Prize. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422236542/en/ Picture of the end of the event with the winners : Bloomineral, Altrove and Iot.Bzh + all the Jury Members from French Automotive OEM and Tier1 Hosted by competition founder Richard de Cabrol and Simon Degiovanni, the evening gathered more than 250 leaders from the automotive, technology, digital, business and media sectors, with attendees joining both on-site and online. Six finalist startups, selected from mor
I/ONX Shatters the Host Tax: New Symphony SixtyFour Architecture Delivers 50% TCO Savings Across AI Inference and Fine-Tuning Lifecycle22.4.2026 15:00:00 CEST | Press release
Eliminating infrastructure overhead of legacy designs, I/ONX debuts a scaled AI inference and fine-tuning stack that cuts power by up to 30kW per rack and reduces cost of rack-scale deployments by up to 70% I/ONX High Performance Compute (HPC), a leading provider of heterogeneous AI systems, today announced the global launch of the Symphony SixtyFour, a high-density platform designed to collapse the physical and economic footprint of AI inference and fine-tuning infrastructure. By supporting up to 64 accelerators on a single node, I/ONX eliminates the redundant Host Tax—the massive overhead in power, hardware, and licensing that negatively impacts ROI in enterprise AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422485327/en/ I/ONX Introduces Symphony SixtyFour: The Host Tax is Over. Save 30-50% on your AI Infrastructure Costs. While inference now accounts for 90% of enterprise AI workloads, enterprises are entirely li
Thales Introduces Imperva for Google Cloud, Bringing Its Enterprise-Grade Application Security Capabilities Directly into Google Cloud22.4.2026 15:00:00 CEST | Press release
New offering eliminates the need to choose between cloud-native performance and advanced security as enterprises scale modern applications Thales today announced the Controlled Availability of Imperva for Google Cloud, bringing the industry's most trusted application security platform directly into Google Cloud. Designed to operate within Google Cloud, the new offering enables organizations to protect web applications and APIs by leveraging Google Cloud’s Service Extension traffic, preserving existing pipelines, integrations, and monitoring workflows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422746638/en/ ©Thales As enterprises accelerate cloud adoption, development teams increasingly standardize on native cloud services to improve speed and reduce operational complexity. Many security solutions, however, require external routing that introduces latency and friction. At the same time, native cloud security tools oft
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom